Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of didemnin-B in advanced epithelial ovarian cancer

A Southwest Oncology Group Study

  • Clinical Studies
  • Published:
Investigational New Drugs Aims and scope Submit manuscript

Summary

A Phase II study of Didemnin-B, a marine cyclic depsipeptide, was undertaken in patients with progressive epithelial ovarian cancer. The starting dose was 2.6 mg/m2. Fifteen patients received the drug, of whom twelve were evaluable. There were no responses observed in the twelve patients. The two most frequent toxicities were nausea and vomiting and anemia. On the basis of this trial, Didemnin-B is not felt to have significant effect with epithelial ovarian cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Rhineart KL Jr., Grever JB, Hughes RG, Swynenberg EG, Stringfellow DA, Kuentzel SL, Li LH: Didemnins: antiviral and antitumor depsipeptides from a Caribbean Tunicate Science 212:933, 1981

    Google Scholar 

  2. Chun HG, Davies B, Hoth D, Suffness M, Yun S: Didemnin-B: The first marine compound entering clinical trials as an antineoplastic agent. Invest New Drugs 4(3):279–84, 1986

    Google Scholar 

  3. Weiss GR, Arteaga C, Brown TD, Craig JB, Harman GS, Havlin KA, Koehler JH, Kuhu JG, Von Hoff DD: New anticancer agents. Ca Chemo Biol Res Modif 10:85–116, 1988

    Google Scholar 

  4. Ziang TL, Liu RL, Salman RF: Antitumor activity of didemnin-B in the human tumor stem cell assay. Cancer Chemotherapy Pharmacol 11:1, 1983

    Google Scholar 

  5. Miller A, Hoogstranten B, Staquet M, Winkler A: Reporting results of cancer treatment. Cancer 47:207–214, 1981

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Puget Sound Oncology Consortium, Seattle, WA, USA

    Joanna M. Cain

  2. Southwest Oncology Group Statistical Center, Seattle, WA, USA

    P. Y. Liu & Janet O'Sullivan

  3. University of Arizona Cancer Center, Tucson, AZ, USA

    David E. Alberts

  4. University of Kentucky Medical Center, Lexington, KY, USA

    Holly H. Gallion

  5. Columbus CCOP, Columbus, OH, USA

    Leslie Laufman

  6. University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    Geoffrey Weiss

  7. Louisiana State University Medical Center, New Orleans, LA, USA

    John N. Bickers

Authors
  1. Joanna M. Cain
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Y. Liu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. David E. Alberts
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Holly H. Gallion
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Leslie Laufman
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Janet O'Sullivan
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Geoffrey Weiss
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. John N. Bickers
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cain, J.M., Liu, P.Y., Alberts, D.E. et al. Phase II trial of didemnin-B in advanced epithelial ovarian cancer. Invest New Drugs 10, 23–24 (1992). https://doi.org/10.1007/BF01275473

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01275473

Key words

Search

Navigation